muc2 antibody, The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope.

The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope.

MUC2 glycoprotein, produced by the epithelium of the colon and constructed up primarily of repeat items of (1) PTTTPITTTTTVTPTPTPTGTQT(23) , could be overexpressed or underglycosylated in gastrointestinal illnesses, e.g. in case of colon carcinoma. We have now been finding out the epitope construction of the MUC2 by specializing in the repeat unit with the mucin peptide particular MAb 996 monoclonal antibody.
This antibody acknowledges the (18) PTGTQ(22) sequence as minimal, and (16) PTPTGTQ(22) as optimum epitope throughout the underglycosylated glycoprotein. On this article, we intention to make clear the impact of glycosylation of the epitope on MAb 996 antibody binding together with its correlation with the secondary construction of the modified peptides: glycosylation within the epitope core and within the flank.
For this we have now ready the (16) PTPTGTQ(22) peptide glycosylated with N-acetylgalactoseamine (Tn antigen) in place 17, 19, 21, or on all three threonines. The MAb 996 antibody binding properties of the peptides had been characterised in aggressive ELISA experiments, and their resolution secondary construction was studied by round dichroism spectroscopy in water and within the ordered construction selling trifluoroethanol.
Our outcomes present that glycosylation in place 19 (peptide (16) PTPT(GalNAcα)GTQ(22) ) resulted in enhanced antibody recognition and considerably altered secondary construction, whereas glycosylation in place 21 fully demolished the binding. These findings might be helpful in figuring out the character of antigen-antibody interplay, and maybe designing artificial peptide vaccines for tumor remedy.

EXPRESSION OF MUC2 GLYCOPROTEIN ANTIBODY AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN BARRETT’S MUCOSA.

Greater expression of the mucin 2 (MUC2) glycoprotein and vascular endothelial development issue (VEGF) in Barrett’s mucosa could also be related to a better danger of esophageal adenocarcinoma growth. Thirty-six sufferers recognized with Barrett’s esophagus (BE), short-segment, had been included within the research on account of unsuccessful remedy with proton pump inhibitors. The prognosis was confirmed by histopathologic evaluation of the tissue obtained by esophagogastric junction biopsy. Expression of MUC2 and VEGF was decided by immunohistochemistry.
We discovered 4 sufferers in early stage of adenocarcinoma and 32 sufferers with BE; 5 of them had indication for argon plasma coagulation remedy, one for radiofrequency ablation and one for endoscopic mucosal resection; 25 sufferers had been handled with proton pump inhibitors. Regression of BE occurred in 25 (69.44%) sufferers. MUC2 positivity is exclusive for goblet cells in sufferers with BE, however it’s not the one marker. VEGF is an indicator of angiogenesis within the mucosa of sufferers with BE and adenocarcinoma.
muc2 antibody, The effect of glycosylation on the antibody recognition of a MUC2 mucin epitope.

Impact of core epitope modification on the antibody recognition of a MUC2 mucin peptide.

Identification of protein epitopes through combinatorial chemistry was one of the crucial essential discoveries of the previous three many years. Mapping of linear antibody epitopes could be achieved quickly and cost-effectively by the polymer pin-bound peptide method.
On this article, the willpower of the fantastic epitope construction of MUC2 mucin glycoprotein is described by utilizing particular monoclonal antibody. We have now used positional scanning combinatorial method, and in addition parallel synthesis. The residues throughout the MUC2 epitope (18)PTGTQ(22) of MAb 996 had been changed by all different proteinogenic amino acids on pin-bound peptide libraries, and their antibody binding was studied in modified ELISA.
Thr(19) was the least essential of the residues in antibody recognition; a lot of the different amino acids might be changed, besides Professional. The opposite residues can’t be changed with out lack of antibody binding, the place each the dimensions and character of the amino acids had been essential.
The importance of the non-chiral Gly(20) residue was additional studied by aggressive ELISA of parallelly synthesized soluble peptides containing L – or D-Ala as a substitute of Gly residue. Nevertheless, the D-Ala-containing oligopeptides confirmed no antibody binding; subsequently, the spine conformation is attribute of that of L-amino acid containing peptides on this place as nicely.
With the combinatorial method we obtained related details about the contribution of particular person amino acid aspect chains to the MAb 996 antibody binding throughout the PTGTQ predominant MUC2 mucin epitope. These outcomes might be utilized for the design of artificial antigens for detection of MUC2 protein core-specific antibodies associated to carcinoma(s).

Irregular subcellular distribution of mature MUC2 and de novo MUC5AC mucins in adenomas of the rectum: immunohistochemical detection utilizing non-VNTR antibodies to MUC2 and MUC5AC peptide.

Anti-mucin variable quantity tandem repeat (VNTR) antibodies have been used beforehand to show the de novo presence of MUC5AC and MUC6 mucin in colorectal adenomas and elevated synthesis of MUC2, the main secreted mucin in regular colorectal mucosa.
Right here we examined secreted mucins in tubular, tubulovillous and villous adenomas of the rectum utilizing non-VNTR antibodies designed to evaluate mature mucin. Mucin gene messenger RNAs had been detected by in situ hybridization. The anti-MUC2 non-VNTR antibody within the goblet cells of adenomas revealed a staining sample of elevated cytoplasmic, Golgi and membrane staining with no change in goblet vesicle reactivity in contrast with regular controls.
As well as, clean goblet cell vesicle immunostaining for MUC2 was discovered within the transitional mucosa adjoining to all varieties of adenoma. Though a pattern to overexpression of MUC2 was noticed with in situ hybridization this was not detected with immunohistology. De novo synthesis of MUC5AC, however not MUC5B or MUC6 mucin was seen in all adenomas and transitional mucosa utilizing immunohistochemistry.
There was no correlation of MUC2 or MUC5AC mucin with polyp dimension or the grade of dysplasia utilizing the non-VNTR antibodies. This research demonstrates that anti-mucin non-VNTR antibodies reveal a unique subcellular-localization in rectal adenomas in contrast with regular colorectal mucosa. Additional, this sample is in distinction to that reported for anti-mucin VNTR antibodies. Mixed use of those reagents might profit future evaluation of those cancers.

Identification and resolution conformation of a number of epitopes acknowledged by a MUC2 mucin-specific monoclonal antibody.

We have now recognized the optimum epitope, 21TQTPT25, within the tandem repeat of mucin 2 (MUC2) glycoprotein by utilizing glycoprotein-specific monoclonal antibody, MAb 994, and artificial, overlapping and truncated oligopeptides equivalent to the sequence 13TPTPTPTGTQTPTT26.
We discovered that peptides containing the 21TQTPT25 sequence had been capable of inhibit the 994 antibody binding and in addition peptides 21TQTPT25 and 17TPTGTQTPT25 had been probably the most inhibitory compounds with the bottom IC50 worth (IC50=four and three microM, respectively) examined.
Curiously, 21TQTPT25 peptide adopts an unordered construction even in TFE, a solvent that promotes an ordered conformation, as detected by round dichroism and Fourier-transform infrared spectroscopy. Nevertheless, Thr at place 26 or amidation of Thr25 on the C-terminus ends in a a lot weaker (three orders of magnitude) MAb interplay, which could be as a result of presence of a flip conformation in peptides with a T26 or an amide C-terminus.

Rat Mucin 2 (MUC2) ELISA Kit

DLR-MUC2-Ra-48T 48T
EUR 508
  • Should the Rat Mucin 2 (MUC2) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Mucin 2 (MUC2) in samples from tissue homogenates, cell lysates or other biological fluids.

Rat Mucin 2 (MUC2) ELISA Kit

DLR-MUC2-Ra-96T 96T
EUR 661
  • Should the Rat Mucin 2 (MUC2) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Mucin 2 (MUC2) in samples from tissue homogenates, cell lysates or other biological fluids.

Human Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Hu-48Tests 48 Tests
EUR 500

Human Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Hu-96Tests 96 Tests
EUR 692

Mouse Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Mu-48Tests 48 Tests
EUR 511

Mouse Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Mu-96Tests 96 Tests
EUR 709

Rat Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Ra-48Tests 48 Tests
EUR 534

Rat Mucin 2 (MUC2) ELISA Kit

RDR-MUC2-Ra-96Tests 96 Tests
EUR 742

Human Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Hu-48Tests 48 Tests
EUR 478

Human Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Hu-96Tests 96 Tests
EUR 662

Mouse Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Mu-48Tests 48 Tests
EUR 489

Mouse Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Mu-96Tests 96 Tests
EUR 677

Rat Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Ra-48Tests 48 Tests
EUR 511

Rat Mucin 2 (MUC2) ELISA Kit

RD-MUC2-Ra-96Tests 96 Tests
EUR 709

MUC2 antibody

22938-100ul 100ul
EUR 390

MUC2 antibody

70R-10672 1 ml
EUR 373
Description: Rabbit polyclonal MUC2 antibody

MUC2 antibody

70R-12547 100 ul
EUR 457
Description: Affinity purified Rabbit polyclonal MUC2 antibody

MUC2 Antibody

37169-100ul 100ul
EUR 252

MUC2 Antibody

10R-11459 500 ul
EUR 613
Description: Mouse monoclonal MUC2 antibody

MUC2 Antibody

49518-100ul 100ul
EUR 333

MUC2 Antibody

49518-50ul 50ul
EUR 239

MUC2 Antibody

DF8390 200ul
EUR 304
Description: MUC2 Antibody detects endogenous levels of total MUC2.

MUC2 Antibody

1-CSB-PA572200
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against MUC2. Recognizes MUC2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

MUC2 Antibody

1-CSB-PA207869
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against MUC2. Recognizes MUC2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

MUC2 Antibody

1-CSB-PA015222LA01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against MUC2. Recognizes MUC2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA

MUC2 Antibody

ABD8390 100 ug
EUR 438

MUC2 Antibody

ABD8395 100 ug
EUR 438

Anti-MUC2 Antibody

A01212 100ug/vial
EUR 334

MUC2 Conjugated Antibody

C49518 100ul
EUR 397

MUC2(CCP58) Antibody

BNUB0032-100 100uL
EUR 209
Description: Primary antibody against MUC2(CCP58), Concentration: 0.2mg/mL

MUC2(CCP58) Antibody

BNUB0032-500 500uL
EUR 458
Description: Primary antibody against MUC2(CCP58), Concentration: 0.2mg/mL

MUC2(CCP58) Antibody

BNUM0032-50 50uL
EUR 395
Description: Primary antibody against MUC2(CCP58), 1mg/mL

MUC2 Conjugated Antibody

C37169 100ul
EUR 397

MUC2(CCP58) Antibody

BNC040032-100 100uL
EUR 199
Description: Primary antibody against MUC2(CCP58), CF405S conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC040032-500 500uL
EUR 544
Description: Primary antibody against MUC2(CCP58), CF405S conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC610032-100 100uL
EUR 199
Description: Primary antibody against MUC2(CCP58), CF660R conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC610032-500 500uL
EUR 544
Description: Primary antibody against MUC2(CCP58), CF660R conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC470032-100 100uL
EUR 199
Description: Primary antibody against MUC2(CCP58), CF647 conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC470032-500 500uL
EUR 544
Description: Primary antibody against MUC2(CCP58), CF647 conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC550032-100 100uL
EUR 199
Description: Primary antibody against MUC2(CCP58), CF555 conjugate, Concentration: 0.1mg/mL

MUC2(CCP58) Antibody

BNC550032-500 500uL
EUR 544
Description: Primary antibody against MUC2(CCP58), CF555 conjugate, Concentration: 0.1mg/mL
We have now additionally noticed that MAb 994 acknowledged two different pentapeptides with the TX1TX2T motif, like 13TPTPT17 (IC50=180 microM) and 19TGTQP23 (IC50=65 microM), whose sequences are current within the native glycoprotein. These findings would possibly counsel that within the MUC2 tandem repeat unit there are a number of antigenic websites obtainable for recognition in underglycosylated tumor tissue and in addition clarify the heteroclitic nature of MAb 994.

Leave a Reply

Your email address will not be published. Required fields are marked *